Immune_JJ
functions_NNS
,_,
clinical_JJ
parameters_NNS
and_CC
hormone_NN
receptor_NN
status_NN
in_IN
breast_NN
cancer_NN
patients_NNS
._.

We_PRP
have_VBP
carried_VBN
out_RP
a_DT
detailed_JJ
analysis_NN
of_IN
the_DT
cellular_JJ
immune_JJ
functions_NNS
of_IN
breast_NN
cancer_NN
patients_NNS
in_IN
comparison_NN
with_IN
healthy_JJ
controls_NNS
._.

A_DT
possible_JJ
correlation_NN
between_IN
immune_JJ
and_CC
clinical_JJ
parameters_NNS
was_VBD
analyzed_VBN
in_IN
50_CD
breast_NN
cancer_NN
patients_NNS
._.

Immune_JJ
parameters_NNS
,_,
natural_JJ
killer_NN
cell_NN
and_CC
T_NN
lymphocyte_NN
functions_NNS
and_CC
the_DT
numbers_NNS
of_IN
circulating_VBG
T_NN
lymphocytes_NNS
were_VBD
analyzed_VBN
against_IN
the_DT
clinical_JJ
parameters_NNS
comprising_VBG
the_DT
tumor_NN
burden_NN
,_,
the_DT
stage_NN
of_IN
the_DT
disease_NN
and_CC
the_DT
expression_NN
of_IN
hormone_NN
receptors_NNS
on_IN
the_DT
tumor_NN
._.

In_IN
order_NN
to_TO
analyze_VB
the_DT
immune_JJ
function_NN
data_NNS
effectively_RB
,_,
low_JJ
responders_NNS
were_VBD
identified_VBN
with_IN
stringent_JJ
cut-off_JJ
values_NNS
._.

Considerably_RB
higher_JJR
proportions_NNS
of_IN
low_JJ
responders_NNS
were_VBD
found_VBN
among_IN
the_DT
patient_NN
population_NN
._.

Elevated_JJ
numbers_NNS
of_IN
circulating_VBG
T_NN
lymphocytes_NNS
and_CC
CD3-directed_JJ
cytolysis_NN
correlated_VBD
with_IN
the_DT
expression_NN
of_IN
estrogen_NN
receptors_NNS
independently_RB
of_IN
the_DT
clinical\/histological_JJ
parameters_NNS
._.

